OTRK Earnings

OTRK reported its FY2024Q2 earnings on 2024-08-08, showcasing a revenue of 2.45M against an estimate of 2.60M, resulting in a -5.73% surprise. The EPS was 0, surpassing the expected -0.1 by 0%. The stock experienced a -4.55% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following OTRK's FY2024Q2 earnings announcement on 2024-08-08, the stock price moved by -4.55% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, OTRK's stock price tends to shift by an average of 23.13% in the 10 days leading up to earnings and -16.27% in the 10 days following, providing insight into potential market.

For 2025/Q2, analysts estimate OTRK's annual revenue to reach 2.40M, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between OTRK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OTRK's stock price typically moves by 23.13% in the 10 days before its earnings and -16.27% in the 10 days after. For the upcoming 2025/Q2 earnings, analysts expect an EPS of undefined and revenue of 2.40M.

Despite enrollment growth and strategic initiatives, the company faces significant challenges: a 25% YoY revenue decrease, reduced gross margins, and ongoing cash flow issues. The positive aspects, such as NCQA certification and potential revenue growth, are overshadowed by reliance on new contracts and financial strain. The lack of significant Q&A insights further supports a negative outlook. Overall, the negatives outweigh the positives, suggesting a potential stock price decline of 2% to 8%.